TAK Circulator

We are developing innovative drugs for severe asthma

“We would be grateful if you could be a business partner and support our drug development”

“TAKC-02” Suppresses both
Eosinophilic and Neutrophilic Inflammation

  • Indications: Steroid-resistant Severe Asthma
  • An antisense oligonucleotide targeting the mRNA of Mex3B
  • Mex3B is an RNA binding protein that induces cytokines involved in airway inflammation
  • Route of administration: inhalation
  • status: non-clinical
Structure of Gapmer-type
antisense oligonucleotide
Activates RNaseH Degrades target mRNA

TAKC-02: Clinical Significance

  • the first drug for neutrophilic severe asthma
  • effective for both neutrophilic and eosinophilic severe asthma

TAKC-02 Suppresses both Eosinophilic and Neutrophilic Inflammation

Ref: The RNA Binding Protein Mex-3B Is Required for IL-33 Induction in the Development of Allergic Airway Inflammation Yamazumi et al Cell Rep. 2016 Aug 30;16(9):2456-71.

TAKC-02 Suppresses both Eosinophilic and Neutrophilic Inflammation